<DOC>
	<DOC>NCT00911794</DOC>
	<brief_summary>The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.</brief_summary>
	<brief_title>Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease</brief_title>
	<detailed_description>Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<criteria>Diagnosis of COPD or Pulmonary Fibrosis First time participants in Pulmonary Rehabilitation program Dementia Prior significant psychiatric illness Inability to complete the questionnaires Inability cooperate with spirometry Inability or to participate in outpatient followup over the sixmonth</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Dyspnea</keyword>
	<keyword>Written Disclosure Therapy</keyword>
	<keyword>COPD</keyword>
	<keyword>Pulmonary Fibrosis</keyword>
	<keyword>Chronic Lung Diseases</keyword>
	<keyword>Pulmonary Rehabilitation</keyword>
</DOC>